PROCEPT BioRobotics Corporation
NASDAQ:PRCTMedical - Devices
+$0.19 today
- Market cap
- $1.45B
- Beta
- 0.85
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.81
Volume 2.05M
Average 1.46M
PRCT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
PROCEPT BioRobotics CorporationNASDAQ: PRCT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$29.09M, compared with -$22.39M a year earlier. Trailing-twelve-month EBITDA was -$92.11M.
Context
- EBITDA amounted to 27.7% of revenue in FY2025, down 8.8 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of -$81.99M (+4.0%) for the fiscal year ending Dec 2026, a step up from the -4.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$29.09M-7.5% QoQ
- Last fiscal yearDec 2025
- -$85.41M-4.2% YoY
- LTMMar 2026
- -$92.11M-14.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -29.9% | -38.3% | -8.4 pp |
| 1 year | -4.2% | +4.0% | +8.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (85.41M) USD
- Year-over-year change
- -4.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (85.41M) | -4.2% |
| FY2024 | 2024-12-31 | (82M) | +16.4% |
| FY2023 | 2023-12-31 | (98.1M) | -24.0% |
| FY2022 | 2022-12-31 | (79.13M) | -56.0% |
| FY2021 | 2021-12-31 | (50.72M) | — |
EBITDA vs competitors
How PRCT compares with its peers on the latest reported figures
- PRCT's LTM Mar 2026 EBITDA of -$92.11M is the lowest of the 5 companies compared; the peer median is -$18.91M.
- Its year-over-year change of -14.2% is the 2nd highest of 4, against a peer median of -22.2%.
- EBITDA amounts to 28.6% of revenue for PRCT, versus a peer median of 45.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$3.71M | +78.9% | — | 7.7% | |
| LTM Mar 2026 | -$14.17M | -22.2% | — | 13493.3% | |
| LTM Mar 2026 | -$23.66M | -24.4% | — | 58.2% | |
FOCLEDAP TMS S.A. American Depositary Shares | LTM Mar 2026 | -$24.59M | — | — | 33.2% |
| LTM Mar 2026 | -$92.11M | -14.2% | — | 28.6% | |
| Peer median (excluding PRCT) | -$18.91M | -22.2% | — | 45.7% | |
Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.47M | 75.01M | 136.19M | 224.5M | 308.05M |
| Cost of Revenue | 18.61M | 37.93M | 65.14M | 87.4M | 111.83M |
| Gross Profit | 15.87M | 37.09M | 71.05M | 137.1M | 196.23M |
| Gross Margin | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| Research & Development | 18.99M | 28.98M | 48.45M | 62.3M | 71.28M |
| Selling, General & Admin | 51.04M | 88.83M | 131.77M | 171.42M | 228.81M |
| Operating Expenses | 70.03M | 117.81M | 180.22M | 233.71M | 300.09M |
| Depreciation & Amortization | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M |
| EBITDA | (50.72M) | (79.13M) | (98.1M) | (82M) | (85.41M) |
| EBITDA Margin | -147.1% | -105.5% | -72.0% | -36.5% | -27.7% |
| Operating Income | (54.16M) | (80.72M) | (109.17M) | (96.61M) | (103.86M) |
| Operating Margin | -157.1% | -107.6% | -80.2% | -43.0% | -33.7% |
| Interest Income | 76K | 2.5M | 7.55M | 10.9M | 12.22M |
| Interest Expense | 5.81M | 5.18M | 4M | 4.18M | 3.59M |
| Other Income / Expenses | (5.69M) | (6.43M) | 3.27M | 5.2M | 8.48M |
| Income Before Tax | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.38M) |
| Pre-Tax Margin | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 190K |
| Net Income | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.57M) |
| Net Margin | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| EPS (Basic) | (1.37) | (1.96) | (2.24) | (1.75) | (1.72) |
| EPS (Diluted) | (1.37) | (1.96) | (2.24) | (1.75) | (1.72) |
| Weighted Avg Shares | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M |
| Weighted Avg Shares (Diluted) | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M |
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
Intrinsic Alpha fair value
Locked
Current Price
$25.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.